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Purpose of the Study
Simplified antiretroviral (ARV) regimens may promote
adherence and improve outcomes in HIV-1 infected
patients. Clinical studies have previously demonstrated
greater adherence with LPV/r SGC when dosed once-daily
(QD) compared to twice-daily (BID). The objectives of
the current analysis are to compare adherence when LPV/
r tablets and SGC are dosed QD and BID and to assess pre-
dictors of early adherence.
Methods
M05-730 is an ongoing Phase III, open-label, rand-
omized, multicenter, multicountry study designed to eval-
uate the safety, tolerability, pharmacokinetics, and
antiviral activity of LPV/r tablets dosed QD or BID
through 48 and 96 weeks in combination with TDF and
FTC (both QD) in ARV naïve HIV-1 infected subjects. In
addition, the study compared safety, tolerability, and
pharmacokinetics of LPV/r tablets with LPV/r SGC over
the first 8 weeks of administration. Electronic monitoring
(MEMS®) allowed for computation of three LPV/r compli-
ance measures through week 12: taking (TAC; prescribed
doses taken), correct dosing (COD; days with correct
number of doses taken), and timing (TIC; doses taken
within ± 3 hrs of prescribed interval) compliance. Using
longitudinal mixed models, demographic and baseline
characteristics were examined for possible associations
with compliance through week 12.
Summary of Results
A total of 606 subjects were included in the analysis.
Adherence was similar for subjects taking LPV/r tablets
compared to SGC. Adherence to LPV/r dosed QD was sta-
tistically significantly greater than BID (p < 0.001). Adher-
ence declined significantly over time (p < 0.001), but
between-arm differences remained consistent over 12
weeks (p = 0.353). Week 48 clinical outcomes did not dif-
fer for subjects receiving LPV/r QD or BID. Demographic
and baseline characteristics significantly associated with
early compliance included sex, age, race, tobacco use,
HIV/AIDS risk factors, HIV-1 RNA, and CD4 and CD8+ T-
cell count (p = 0.20). The strongest associations were for
TIC and sex (M>F), age (older>younger) and race
(white>black) (p ≤ 0.003); however, the proportion of
subjects with plasma HIV-1 RNA <50 copies/mL at week
48 did not differ by sex (p = 0.622), race (p = 0.724) or age
(p = 0.610).
Conclusion
In this large study of LPV/r, QD dosing resulted in higher
levels of adherence than BID dosing. Adherence to LPV/r
tablets and SGC were similar. Sex, age and race were pre-
dictors of early adherence. Differences in early adherence
did not predict clinical outcomes in this study.
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